

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

December 2, 2019

Alexander Arrow Chief Financial Officer Protagenic Therapeutics, Inc.\new 149 Fifth Avenue New York, New York 10010

> Re: Protagenic Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2018 Response dated November 25, 2019 File No. 000-51353

Dear Mr. Arrow:

We have reviewed your November 25, 2019 response to our comment letter and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to this comment, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our October 23, 2019 letter.

Correspondence filed November 25, 2019

Note 5 Derivative Liabilities, page F-14

1. We read your response to comment 3. It appears your warrants meet the definition of a derivative; however, please provide us with your analysis of whether the warrants should be classified as a liability or equity. Refer to guidance in ASC 805-40-25.

Alexander Arrow Protagenic Therapeutics, Inc.\new December 2, 2019 Page 2

You may contact Tony Watson at (202) 551-3318 or Bill Thompson at (202) 551-3344 if you have questions regarding comments on the financial statements and related matters.

Sincerely,

Division of Corporation Finance Office of Trade & Services